Loading...
•
Jun 30, 2021
Wave Life Sciences Q2 2021 Earnings Report
Wave Life Sciences announced financial results for the second quarter ended June 30, 2021 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $38.8 million in the second quarter of 2021. The company's cash and cash equivalents totaled $143.8 million as of June 30, 2021, and expects existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Dosing is underway in the FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD, which is the first oligonucleotide using PN backbone chemistry modifications in clinical study.
Recruitment is ongoing for clinical trials in HD and DMD.
The company is generating clinical data in multiple trials through 2022 to enable decision making.
Leading endogenous ADAR editing capability demonstrated restoration of functional AAT protein in vivo; new data will be presented at Wave Research Day on September 28.
Forward Guidance
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...